Beam Therapeutics Inc.
BEAMHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. With a market capitalization of $2.83B, it sits in mid-cap territory. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Market Cap
$2.83B
Beta
2.18
P/E (TTM)
—
P/E (Fwd)
-5.82
EPS (TTM)
$-0.48
EPS (Fwd)
$-4.73
ROE
-5.8%
ROA
-15.8%
Cash
$1.21B
Total Debt
$250.8M
Free CF
-$233.6M
52W Change
32.7%
Annual Financials
Cash vs Debt
With $1.21B in cash and $250.8M in debt, BEAM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$233.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -5.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $60.9M (2022) to $139.7M (2025), reflecting a 129% increase over the period.
Beam Therapeutics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, BEAM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Beam Therapeutics Inc.'s trajectory.